iBio, Inc. - Common Stock (IBIO)
Frequently Asked Questions About iBio, Inc. - Common Stock (IBIO)
Does iBio have a pipeline of products?
Yes, iBio has a pipeline that includes several therapeutic candidates in various stages of development. The company actively works on advancing its product candidates through research, clinical trials, and regulatory processes to bring them to market.
Has iBio received any funding or government grants?
Yes, iBio has been awarded grants from various government agencies to support specific research initiatives, particularly those related to pandemic response and the development of therapeutics. This funding helps to facilitate research and accelerate the timeline for bringing products to market.
How can I invest in iBio?
Investing in iBio can be done through a licensed brokerage firm or online trading platform that provides access to the NYSE. Investors should conduct thorough research or consult with financial advisors before making investment decisions.
How does iBio contribute to vaccine development?
iBio plays a significant role in vaccine development by utilizing its FastPharming Technology to rapidly produce vaccine candidates. This approach can be particularly valuable in responding to emerging infectious diseases, where quick vaccine development is critical.
How does iBio ensure quality in its products?
iBio implements rigorous quality control measures throughout the production process to ensure that its biologics meet the necessary safety and efficacy standards. These measures align with regulatory requirements and include testing and validation of its processes.
How does iBio fund its operations?
iBio funds its operations through a combination of equity financing, grants, and collaborations with partners. This multi-faceted approach provides the company with the resources necessary to invest in research, development, and commercialization of its products.
How does iBio plan to grow in the future?
iBio plans to grow by advancing its clinical programs, expanding its pipeline of therapeutic candidates, and potentially entering new markets. The company also aims to leverage collaborations and partnerships to enhance its research capabilities and accelerate product development.
How does iBio's vaccine development process work?
iBio's vaccine development process utilizes its proprietary plant-based expression technology to produce antigens that stimulate an immune response. This approach allows for faster development times and cost-effective manufacturing compared to traditional methods.
Is iBio involved in any collaborations to combat COVID-19?
Yes, iBio is actively involved in collaborations to develop vaccines and therapies aimed at combatting COVID-19. The company's plant-based technology is being utilized to create candidates that are currently undergoing preclinical and clinical evaluations.
Is iBio publicly traded?
Yes, iBio, Inc. is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol 'IBIO.' This allows investors to buy and sell shares and provides the company with access to capital markets to fund its research and development efforts.
Is iBio, Inc. publicly traded?
Yes, iBio, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'IBIO'. The company went public through a reverse merger and has raised funds via public offerings to support its research and development activities.
What are the key challenges facing iBio?
iBio, like many biotechnology companies, faces challenges such as regulatory hurdles, competition in the biotech space, and the need for significant investment in research and development. Navigating these challenges is crucial for the company's success and growth.
What are the potential applications of iBio's technologies?
iBio's technologies have potential applications in various fields such as vaccine development, therapeutic treatments for chronic diseases, and even agricultural uses. The ability to produce biologics rapidly opens up numerous pathways for innovation.
What are the primary applications of iBio's technology?
The primary applications of iBio's technology include the development of vaccines for infectious diseases and therapeutic antibodies for cancer treatment. The versatility of the plant-based expression platform allows for rapid adaptation to create various biological products.
What challenges does iBio face?
Like many biotech companies, iBio faces challenges including regulatory hurdles, competition in the biotech space, and the need for significant funding to support research and development. Additionally, the success of its products depends on successful clinical trials and market acceptance.
What competitive advantages does iBio claim?
iBio claims several competitive advantages, including its unique plant-based expression technology that allows for faster production times, lower costs, and increased scalability compared to traditional mammalian cell systems. This positions iBio well in the rapidly evolving biotech landscape.
What does iBio, Inc. do?
iBio, Inc. is a biotechnology company specializing in the development of innovative products for the prevention and treatment of infectious diseases and cancer. Utilizing its proprietary plant-based protein expression technology, iBio aims to produce therapeutics quickly and cost-effectively.
What is iBio's approach to sustainability?
iBio's plant-based technology is designed to be more sustainable than traditional methods of biologics production, as it can reduce waste and lower the environmental footprint associated with manufacturing. The company is committed to promoting sustainability within the biotech industry.
What is iBio's proprietary technology?
iBio has developed a proprietary plant-based protein expression system known as the iBioLaunch platform. This system harnesses the unique properties of plants to produce proteins rapidly and efficiently, enabling the development of pharmaceutical products.
What is iBio's vision for the future?
iBio envisions becoming a leader in biologics production by continuously advancing its FastPharming Technology and expanding its product offerings. The company aims to address unmet medical needs while also contributing to global health through innovative biotherapeutics.
What is the company’s approach towards innovation?
Innovation is at the core of iBio's operations, and the company is dedicated to exploring cutting-edge technologies and methodologies in biotech. They invest in research and collaborations to foster the development of new solutions for biological challenges.
What is the FastPharming Technology?
FastPharming Technology is iBio's proprietary method to produce biologics using transgenic plants. This system significantly reduces the time and cost associated with producing therapeutic proteins and antibodies, as it allows for scalable and fast production cycles compared to traditional methods.
What is the significance of iBio's facility in Bryan, Texas?
iBio's facility in Bryan, Texas, is a crucial component of its operations, designed specifically for the production of biologics using its plant-based technology. This facility supports both research and commercial-scale manufacturing, enhancing the company's ability to bring products to market.
What is the significance of iBio's stock performance?
iBio's stock performance can be indicative of the broader market's evaluation of the company's potential and growth prospects. Investors typically watch stock movements closely as they reflect market sentiment regarding the company's developments and strategic initiatives.
What is the status of iBio's clinical programs?
As of October 2023, iBio has several clinical programs in development, targeting diseases such as COVID-19 and various types of cancer. The company continues to advance its vaccine candidates through preclinical and clinical trials.
What partnerships does iBio have?
iBio has formed strategic partnerships with several organizations and academic institutions to enhance its research capabilities and accelerate the development of its therapeutic candidates. These collaborations often involve shared resources and expertise.
What recent developments has iBio announced?
iBio has announced several recent developments, including advancements in its clinical trials for COVID-19 vaccines and updates on its cancer therapeutic candidates. These announcements often include partnerships, research updates, or milestones achieved in the development process.
What types of investors does iBio attract?
iBio attracts a variety of investors, including institutional investors, venture capitalists, and individual retail investors. The company's innovative approach to biotechnology and potential for growth in the market appeals to those looking to invest in the life sciences sector.
What types of products does iBio develop?
iBio develops a range of biologic products, including vaccines and therapeutics for infectious diseases and cancer. The company's expertise in plant-based production also enables it to create customized biologics for various applications.
What types of therapies is iBio focusing on?
iBio is focusing on developing therapies for infectious diseases and cancer. The company aims to provide solutions such as vaccines and monoclonal antibodies that leverage its innovative plant-based technology.
When was iBio, Inc. founded?
iBio, Inc. was founded in 2008. Since its inception, the company has focused on advancing its platform technology and developing a range of therapeutic candidates, especially in the areas of vaccines and therapeutic antibodies.
Where is iBio, Inc. located?
iBio, Inc. is headquartered in Bryan, Texas. The company operates a state-of-the-art facility designed for the production of biologics and conducts research and development activities from this location.
Who are the key executives at iBio?
The leadership team at iBio includes experienced professionals from the biotechnology and pharmaceutical industries. Key executives typically include positions like the CEO, CFO, and other senior management roles, who are responsible for guiding the company's strategic direction and operations.
What is the current price of iBio, Inc. - Common Stock?
The current price of iBio, Inc. - Common Stock is 6.410
When was iBio, Inc. - Common Stock last traded?
The last trade of iBio, Inc. - Common Stock was at 8:00 pm EST on March 3rd, 2025
What is the market capitalization of iBio, Inc. - Common Stock?
The market capitalization of iBio, Inc. - Common Stock is 58.76M
How many shares of iBio, Inc. - Common Stock are outstanding?
iBio, Inc. - Common Stock has 9.17M shares outstanding.